上海赛伦生物技术股份有限公司 2024 年度"提质增效重回报"行动方案评估报告 暨 2025 年度"提质增效重回报"行动方案 为践行以"投资者为本"的上市公司发展理念，持续提升经营质量，规范 治理，维护公司全体股东利益，助力信心提振，上海赛伦生物技术股份有限公 司（以下简称"公司"）持续开展"提质增效重回报"专项行动，对 2024 年度 "提质增效重回报"行动方案执行情况进行评估，并制定了 2025 年度行动方案。 具体情况如下： 一、聚焦经营主业，不断增强综合竞争力 2024 年，公司专注于主营业务的深耕细作，提升核心竞争力，保持了健康 的发展态势；实现营业收入 19,491.59 万元，较上年同期增长 2.51%；实现归属 于上市公司股东的净利润 4,429.04 万元，较上年同期增长 14.23%；实现归属于 上市公司股东的扣除非经常性损益的净利润 2,824.98 万元，较上年同期增长 17.70%。 各主要研发项目稳步推进，进展顺利。2024 年，抗蝰蛇毒血清研发项目进 入临床Ⅱ期试验阶段，多中心临床研究已启动；医疗器械创新产品眼镜蛇毒快 速检测诊断试剂研发项目进入临床试验阶段，部分受试者入组。蜂类 ...

公司代码：688163 公司简称：赛伦生物 上海赛伦生物技术股份有限公司 2024年度内部控制评价报告 上海赛伦生物技术股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变 ...

关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海赛伦生物技术股份有限公司 一、 召开会议的基本情况 （一） 股东大会类型和届次 证券代码：688163 证券简称：赛伦生物 公告编号：2025-008 2024年年度股东大会 召开日期时间：2025 年 5 月 16 日 14 点 30 分 召开地点：上海赛伦生物技术股份有限公司（上海市青浦区华青路 1288 号） 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 16 日 至2025 年 5 月 16 日 股东大会召开日期：2025年5月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时 ...

上海赛伦生物技术股份有限公司（以下简称"公司"）第四届监事会第五次 会议（以下简称"本次会议"）于 2025 年 4 月 25 日以现场结合通讯方式召开， 本次会议通知及相关材料已于 2025 年 4 月 15 日以电子邮件的方式送达公司全体 监事。公司监事 3 人，实际出席监事 3 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规、规范性文件和《公司章程》《监事会议事规则》的有关规定，会议形成的决 议合法、有效。 二、 监事会会议审议情况 经与会监事投票表决，审议通过了如下议案： 1、审议通过《关于 2024 年度监事会工作报告的议案》 2024 年度，公司监事会在公司重大经营决策、公司制度建设、法人治理结 构完善、公司规范运作等方面做了相关工作，有效保证了公司的正常生产经营和 规范化运作。公司监事会按照有关规定编制了《2024 年度监事会工作报告》。 证券代码：688163 证券简称：赛伦生物 公告编号：2025-007 上海赛伦生物技术股份有限公司 第四届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2025-006 上海赛伦生物技术股份有限公司 第四届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会的召开情况 上海赛伦生物技术股份有限公司（以下简称"公司"）第四届董事会第六次 会议（以下简称"本次会议"）于 2025 年 4 月 25 日以现场结合通讯方式召开， 本次会议通知及相关材料已于 2025 年 4 月 15 日以电子邮件的方式送达公司全体 董事。公司董事 9 人，实际出席董事 9 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规、规范性文件和《公司章程》《董事会议事规则》的有关规定，会议形成的决 议合法、有效。 二、 董事会会议审议情况 经与会董事投票表决，审议通过了如下议案： 1、审议通过《关于 2024 年度董事会工作报告的议案》 表决结果：9 票同意；0 票反对；0 票弃权。 本议案尚需提交公司股东大会审议。 2、审议通过《关于 2024 年度总经理工作报告的议案》 表决结果：9 票同 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2025-009 上海赛伦生物技术股份有限公司 关于 2024 年度利润分配方案及 2025 年中期现金分红事项的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2024年度每股分配比例：每10股派发现金红利2.00元（含税），不进行资 本公积金转增股本，不送红股。 2024年度利润分配以实施权益分派股权登记日登记的总股数为基数，具 体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总 额不变，相应调整每股分红比例，并将另行公告具体调整情况。 提请股东大会授权董事会在满足现金分红条件，不影响公司正常经营和 持续发展的情况下，在2025年中期（半年度报告或第三季度报告披露期间）适当 增加一次分红，制定并实施具体现金分红方案。 本次利润分配方案及2025年中期分红事项已经公司第四届董事会第六次 会议及第四届监事会第五次会议审议通过，尚需提交股东大会审议。公司不触及 《上海证券交易所科创板股票上市规则》（以 ...

Financial Performance - The company's operating revenue for 2024 reached ¥194,915,924.94, representing a year-on-year increase of 2.51%[24]. - Net profit attributable to shareholders for 2024 was ¥44,290,403.28, reflecting a growth of 14.23% compared to the previous year[27]. - The net cash flow from operating activities increased by 53.12% year-on-year, amounting to ¥50,253,408.63[27]. - The basic earnings per share for 2024 was ¥0.41, up 13.89% from the previous year[25]. - The company's total assets at the end of 2024 were ¥1,120,033,956.92, showing a slight decrease of 0.75% from the previous year[24]. - The company's net assets attributable to shareholders increased by 0.89% year-on-year, totaling ¥1,095,500,608.75 at the end of 2024[24]. - The comprehensive gross profit margin increased by 2.35 percentage points, and net cash flow from operating activities grew by 53.12% year-on-year[39]. - The total cash dividend for 2024, including the interim distribution, amounts to 34,630,400.00 RMB, representing 78.19% of the net profit attributable to shareholders in the consolidated financial statements for 2024[8]. Research and Development - The company made significant progress in R&D, with key projects like the anti-cobra venom serum entering clinical trial phases[40]. - The total R&D investment for the year is approximately ¥23.84 million, a decrease of 21.61% compared to the previous year[86]. - The company has received authorization for 7 invention patents during the reporting period, bringing the total to 20[84]. - The company has developed core proprietary technologies for the preparation of safe, effective, and stable emergency treatment drugs[75]. - The company is conducting clinical trials for five major projects, including the development of antivenom for viper bites, with a total expected investment of 2,570.00 million RMB and current period investment of 190.01 million RMB[87]. - The company is committed to developing rapid diagnostic reagents for snake venom, aiming to meet clinical needs and create new growth points[161]. - The company is actively pursuing market expansion and innovation in its product offerings, focusing on the development of new biopharmaceuticals and medical devices[140]. Market Position and Products - The company is the sole producer and seller of snake antivenom in China, providing critical emergency treatment for snake bites[46]. - The company holds several patents, including methods for preparing specific polyclonal antibodies against snake venom, enhancing its competitive edge in the market[40]. - The company aims to increase the coverage of its anti-snake venom serum products, which currently only reach a few thousand patients each year due to competition from traditional Chinese medicine[65]. - The company’s main products include anti-viper venom serum, equine tetanus immunoglobulin, and rabies serum, all of which are positioned as leading products in their respective categories[63]. - The company is preparing for the market launch of the anti-rabies serum, which is expected to be a new growth point for performance[42]. - The company is focused on expanding its market presence and improving clinical treatment standards for snakebite injuries, which is expected to drive demand for its products[42]. Governance and Compliance - The company emphasizes effective communication with investors through various channels, including performance briefings and investor hotlines[170]. - The company is committed to optimizing its governance structure and internal controls to protect shareholder rights and promote sustainable development[166]. - The company held two shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[173]. - The board of directors convened eight times, successfully completing board elections and adhering to governance regulations[167]. - The supervisory board met seven times, maintaining compliance with legal frameworks and ensuring oversight of company operations[168]. - The company has not faced any penalties from securities regulatory agencies in the past three years[186]. Risks and Challenges - The company has detailed various operational risks in the report, which investors are advised to review[5]. - Future risks include potential price controls or competition leading to price reductions, which could impact revenue growth and profitability[99]. - The company faces risks related to product safety, particularly concerning the potential presence of pathogens in its antivenom products despite stringent screening measures[98]. - The company has a risk of supply shortages for horses used in the production of antivenom serum due to limited suppliers and potential quarantine issues[101]. - The company faces risks from increased market competition for its main products, which could lead to price declines or reduced market share[103]. Employee and Management - The total number of employees in the parent company and major subsidiaries is 326, with 255 in the parent company and 71 in subsidiaries[198]. - The company has implemented a competitive and incentive-based compensation policy, ensuring timely payment of social insurance and housing fund for all employees[199]. - Employee benefits include free lunch, dormitory, free shuttle bus, high-temperature allowance, annual health check-ups, holiday benefits, birthday benefits, and special benefits for female employees[199]. - The company emphasizes employee training, with annual training plans focusing on practical skills, professional knowledge, and career development[200]. - The company appointed Liu Jinbao as the new CFO effective February 2025, following the resignation of Li Shaoyang for personal reasons[180]. Strategic Plans - The company plans to expand its product line in the anti-serum and anti-toxin sector, focusing on new indications for biological toxin-related diseases, with several products in preclinical or clinical research stages[159]. - The company plans to enhance its product pipeline to improve treatment efficiency for snakebite injuries, thereby expanding its competitive advantage in this field[162]. - The company aims to enhance academic promotion of its products and strengthen market insights, focusing on expanding the market for snake antivenom and rabies serum[162]. - The company plans to accelerate the R&D of new products, including rapid diagnostic kits for snake venom, with clinical studies for cobra venom tests expected to be completed in 2025[162].

Financial Performance - The company's operating revenue for Q1 2025 was ¥25,621,279.55, a decrease of 2.59% compared to ¥26,301,356.47 in the same period last year[4] - Net profit attributable to shareholders increased by 154.77% to ¥3,757,316.22 from ¥1,474,787.04 year-on-year[4] - Basic and diluted earnings per share rose by 200.00% to ¥0.03 from ¥0.01 in the previous year[4] - Total operating revenue for Q1 2025 was ¥25,621,279.55, a decrease of 2.58% from ¥26,301,356.47 in Q1 2024[18] - Net profit for Q1 2025 was ¥3,757,316.22, significantly up from ¥1,474,787.04 in Q1 2024, marking an increase of 154.5%[19] - Basic and diluted earnings per share for Q1 2025 were both ¥0.03, compared to ¥0.01 in Q1 2024[19] - Total comprehensive income for Q1 2025 was ¥3,757,316.22, compared to ¥1,474,787.04 in Q1 2024, reflecting a strong performance[19] Research and Development - Total R&D investment was ¥3,182,878.72, down 48.68% from ¥6,202,207.19 in the same period last year, with R&D expenses accounting for 12.42% of operating revenue, a decrease of 11.16 percentage points[5] - Research and development expenses decreased to ¥3,182,878.72 in Q1 2025 from ¥6,202,207.19 in Q1 2024, a reduction of 48.7%[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥20,933,375.96, slightly improved from -¥21,796,451.38 in the previous year[4] - Cash flow from operating activities for Q1 2025 was negative at -¥20,933,375.96, slightly improved from -¥21,796,451.38 in Q1 2024[22] - Cash flow from investing activities generated a net inflow of ¥189,750,738.98 in Q1 2025, compared to a net outflow of -¥5,046,128.03 in Q1 2024[23] - The ending cash and cash equivalents balance for Q1 2025 was ¥350,924,252.18, up from ¥124,093,875.96 in Q1 2024[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,116,016,974.45, a decrease of 0.36% from ¥1,120,033,956.92 at the end of the previous year[5] - The company's total liabilities decreased to ¥17,122,128.87 from ¥24,533,348.17, a reduction of 30.3%[15] - The total assets as of March 31, 2025, were ¥1,116,016,974.45, down from ¥1,120,033,956.92, a decrease of 0.4%[14] - The company's equity attributable to shareholders increased to ¥1,098,894,845.58 from ¥1,095,500,608.75, a rise of 0.2%[15] - The total current assets decreased slightly to ¥912,262,557.85 from ¥916,362,945.70, a decline of 0.4%[13] - Accounts receivable increased to ¥49,203,485.97 from ¥36,678,957.69, reflecting a growth of 34.0%[13] - The inventory level rose to ¥47,473,661.57 from ¥43,275,462.94, an increase of 9.1%[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,061[8] - Major shareholders include Zhao Aixian with 34.05% and Shanghai Zhiyuan Investment Co., Ltd. with 22.18% of shares[9] - The company has not reported any significant changes in its major shareholders or their shareholdings during the reporting period[10] Other Information - The company reported non-recurring gains of ¥3,825,059.39, primarily from bank wealth management income and government subsidies[7] - There are no new strategies or major product developments mentioned in the current report[11] - The company reported a significant increase in investment income, rising to ¥2,266,175.69 in Q1 2025 from ¥645,457.55 in Q1 2024[18] - The company reported a significant decrease in short-term borrowings, reflecting improved liquidity management[15]

上海赛伦生物技术股份有限公司 内 部 控 制 审 计 报 告 天职业字[2025]7682 号 录 目 内 部 控 制 审 计 报 告 - l 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查询 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查询 "我在 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了上 海赛伦生物技术股份有限公司(以下简称"赛伦生物")2024年 12月 31 日的财务报告内部 控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定,建立健全和有效实施内部控制,并评价其有效性是赛伦生物董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制 ...